Can Resistance Enhance Selection of Treatment? (CREST)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

338 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-03-01

Study Completion Date

2006-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare two commercially available platforms for assessment of HIV drug resistance to determine which provides superior virological results.

We hypothesise that one test will be significantly superior to the other.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Comparison of Two Tests for Anti-HIV Drug Resistance

NCT00006490

HIV Infections

COMPLETED

Resistance Testing to Improve Management of Virologic Failure in Sub-Saharan Africa

NCT02787499

HIV AIDS

COMPLETED NA

Dynamics of Drug Resistance-associated Mutations in HIV-1 DNA Reverse Transcriptase Clearance During Effective Antiretroviral Therapy

NCT04448158

HIV-1-infection

COMPLETED

Prevalence of Drug-resistant Hiv-1 Strains in Patients Experiencing Virologic Failure. (MULTIVIR2025)

NCT06842706

HIV Infection

NOT_YET_RECRUITING

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

NCT01363011

Acquired Immunodeficiency Syndrome HIV Infections

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A: subjects assign to receive a GENOTYPE

randomised prior to the selection of their new cART regimen

Group Type EXPERIMENTAL

Blood test: genotype testing

Intervention Type DIAGNOSTIC_TEST

Group B: subjects assign to receive a VIRTUAL PHENOTYPE

randomised prior to the selection of their new cART regimen

Group Type EXPERIMENTAL

Blood test: genotype testing

Intervention Type DIAGNOSTIC_TEST

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood test: genotype testing

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIV infected patients taking combination antiretroviral therapy, with plasma HIV RNA\> 2000copies/mL, who were willing to change ARVs and who provided informed consent.

Exclusion Criteria

* Patients who were ARV naïve, who were experiencing an acute illness or judged to be unable to comply with the protocol requirements.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sean Emery, PhD

Role: STUDY_CHAIR

The National Centre in HIV Epidemiology and Clinical Research at the University of New South Wales

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Interchange General Practice

Canberra, Australian Capital Territory, Australia

Site Status